MAP2K7 and breast cancer: Nevertheless, this is the first study to demonstrate a mechanism of how MEK pathway activation is associated with endocrine therapy resistance of gynecologic cancers by comparing with breast cancers to show the differences in the signaling pathway activation between breast cancers and the gynecologic cancers.